What Is Sermorelin?

What sermorelin is

Sermorelin is a synthetic peptide made of 29 amino acids. Those 29 are not a random fragment — they’re the first 29 amino acids of human growth hormone-releasing hormone (GHRH), the natural hormone your hypothalamus uses to tell your pituitary gland to release growth hormone. The full hormone is 44 amino acids long, but researchers found decades ago that this opening 29-amino-acid stretch carries essentially all of the biological activity. That’s why sermorelin is often written as GHRH (1-29) or GRF 1-29: it’s the shortest piece of the natural signal that still does the natural signal’s job.

So at the simplest level, sermorelin is a lab-made copy of a message your body already sends. It is not growth hormone, and it is not a steroid. It’s a releasing peptide — a prompt.

Note: This page is the orientation page — what sermorelin is and how it fits the wider growth-hormone-peptide landscape. The deeper questions (does it actually do anything, what it costs, how to access it legally, how it compares head-to-head with CJC-1295) each have their own dedicated page, linked throughout.

How it works

Your pituitary gland contains cells called somatotrophs whose job is to manufacture and release growth hormone (GH). Sermorelin binds to the GHRH receptor on those cells and switches them on, prompting them to make and release a pulse of your own growth hormone. That GH then drives production of IGF-1 (insulin-like growth factor 1) in the liver and elsewhere, which is the downstream signal responsible for most of growth hormone’s effects in adults.

The key word is your own. This is the central distinction that defines the whole category:

• Injected HGH (somatropin) floods the body with growth hormone made in a factory. It overrides your natural regulation — your pituitary effectively gets told it doesn’t need to bother.
• Sermorelin asks your pituitary to do its own job a little harder. Because it works one step upstream, the body’s normal feedback brakes stay intact: if GH levels climb too high, a separate hormone (somatostatin) reins the pulse back in. You can’t easily push your system into a sustained, unnaturally flat “GH bleed” the way direct hormone can.

In plain terms: HGH is the product; sermorelin is a nudge to the factory.

That mechanism is genuinely a point in sermorelin’s favor for safety reasoning, and it’s why clinics describe it as “more physiological.” It’s also why effects tend to be more modest than direct hormone — you’re working within the limits of what your own pituitary can still produce, which declines with age and varies a lot person to person.

The short half-life

Sermorelin disappears from the bloodstream fast — its half-life is only about 10 to 12 minutes, because an enzyme called DPP-IV clips it apart quickly. (That’s the same enzyme family that breaks down GLP-1 incretin hormones.) The molecule is gone within roughly an hour, although the GH pulse it triggers outlasts it. This short window matters for understanding sermorelin’s place in the family, and it’s the single biggest reason the modified versions exist (more below).

Where sermorelin sits in the growth-hormone-peptide family

It helps to see sermorelin as the original in a family of peptides that all try to raise your own growth hormone. They split into two broad mechanisms:

GHRH analogs — these copy the GHRH signal and hit the GHRH receptor. Sermorelin is the prototype here. So is CJC-1295, which is built on the very same GRF 1-29 backbone but adds four amino-acid substitutions to resist that fast DPP-IV breakdown, plus an optional “DAC” modification that stretches its half-life from minutes to roughly a week. Sermorelin is essentially CJC-1295’s unmodified ancestor. Tesamorelin (which is FDA-approved, for a specific HIV-related condition) is another, more stabilized GHRH analog. A full side-by-side belongs on the sermorelin vs CJC-1295 page, but the one-line version is: same family, sermorelin is shorter-acting and simpler.

Ghrelin-receptor agonists (GHRPs) — these hit a different receptor entirely, the ghrelin/GHS-R1a receptor, and trigger GH release through a separate door. Ipamorelin is the popular modern example. Because they work through a different pathway, GHRH analogs and ghrelin agonists are sometimes used together; the comparison of those two levers lives on what is CJC-1295 and the CJC/ipamorelin pages.

The practical takeaway for orientation: when you see sermorelin, CJC-1295, ipamorelin, tesamorelin and similar names lumped together as “growth hormone peptides,” they are all secretagogues — they all coax your own GH out rather than supplying it — but they’re not interchangeable. They differ in receptor, half-life, evidence and, importantly, legal status.

Its unusual FDA-approval history

Here’s what genuinely sets sermorelin apart from almost every other peptide discussed on this site: it used to be an FDA-approved drug. Most wellness peptides have never been approved for anything. Sermorelin has two approvals on the record.

• In December 1990, the FDA approved sermorelin acetate as Geref Diagnostic — a single-injection test used to evaluate whether someone’s pituitary could secrete growth hormone properly.
• In September 1997, it approved Geref as a treatment for idiopathic growth hormone deficiency in children with growth failure.

Then in December 2008, the manufacturer (EMD Serono) told the FDA it was discontinuing the products and asked to withdraw the approvals; the FDA withdrew marketing approval effective 2009. The important detail, which the FDA spelled out in a 2013 Federal Register determination, is that Geref was not pulled for reasons of safety or effectiveness. It was a business decision — declining demand for the branded products, and difficulty sourcing the active ingredient at commercial scale.

That history does two things. First, it means sermorelin has a longer and more documented clinical track record than the typical gray-market peptide — it was studied in real human trials and carried by a major manufacturer for years. Second, the “not withdrawn for safety or effectiveness” finding is exactly the kind of regulatory footing that keeps a discontinued molecule available through compounding pharmacies rather than banned outright.

It’s worth being precise about what this does not mean. Sermorelin is not an FDA-approved product you can buy today — no branded, FDA-approved sermorelin is on the market. And its original approvals were for diagnosis and for pediatric GH deficiency, not for the anti-aging, sleep and body-composition uses that drive most adult demand now. Those modern uses are off-label, and the evidence behind them is far thinner than the approval history might suggest. We grade that evidence claim by claim on the sermorelin benefits page rather than here.

Its US legal status in 2026 — calmer than its cousins

If you’ve read anything about peptides in 2026, you’ve seen the turbulence: in April 2026 the FDA removed roughly a dozen peptides — BPC-157, TB-500, MOTS-C, Semax and others — from “Category 2” of its 503A bulk drug substances list, with a Pharmacy Compounding Advisory Committee (PCAC) review scheduled for July 23-24, 2026, and formal rulemaking still to come. Those peptides are, in practical terms, in a holding pattern: no longer flagged as high-risk, but not yet formally cleared for compounding either.

Sermorelin is not part of that story at all — and that’s the headline of its 2026 status. Because of its prior-approval history and long compounding record, sermorelin was never placed on Category 2 in the first place. It didn’t get removed in April 2026 because it was never on the list that’s now being reworked. It has continued to be prescribed and compounded throughout, under the ordinary federal and state compounding frameworks (503A pharmacies, and in many cases FDA-registered 503B outsourcing facilities).

Note: You may see claims online — and even in some source spreadsheets — that sermorelin was “reclassified to Category 1 in February 2026.” Treat that as inaccurate. No peptide has been placed into Category 1 through this process; the February 2026 event was a policy announcement of intent, not a rule, and sermorelin’s availability never depended on it. Sermorelin’s compounded access is settled for the older, simpler reason that it was a previously approved drug that left the market for business reasons.

So in 2026 the honest summary is: sermorelin is not FDA-approved as a finished product, but it is legally prescribable and compoundable, with one of the most stable regulatory footings of any peptide in this space. That stability is a real practical advantage over CJC-1295, whose compounding pathway is comparatively uncertain. The full regulatory picture, including how the broader reclassification works, lives on the 2026 FDA peptide reclassification and are peptides legal in the US. As with anything regulatory, this reflects the situation as of this page’s update date and can change.

How people access it legally

Because sermorelin is a prescription compound rather than an over-the-counter product, legitimate access runs through a licensed prescriber and a licensed pharmacy — never through “research only” vials sold online. The common routes are telehealth platforms (a remote provider evaluates you and, if appropriate, sends a prescription to a partnered compounding pharmacy), in-person wellness or anti-aging clinics, and direct prescriptions from a physician you already see. What separates a legitimate route from a risky one isn’t the molecule — it’s whether there’s a real evaluation, a real prescription, and a licensed pharmacy behind it.

We keep the practical route-by-route comparison, including the 503A-versus-503B distinction that’s unusually relevant for sermorelin, on the how to get sermorelin page, and what it all costs on sermorelin cost. What this page deliberately doesn’t cover is dosing — how much, how often, how to mix anything. Those are clinical decisions a prescriber makes for a specific person, not numbers to copy off a web page, and that’s true even for a molecule with sermorelin’s relatively gentle reputation.

The honest bottom line

Sermorelin is the original growth-hormone-releasing peptide: a 29-amino-acid copy of your body’s own GHRH signal that nudges your pituitary to release more of its own growth hormone, working with your natural feedback rather than overriding it. It’s unusual in this field for having a real FDA-approval history and, partly because of that, an unusually settled legal status in 2026 — it sits outside the Category 2 churn entirely.

What that history doesn’t do is prove sermorelin delivers on the anti-aging and body-composition promises that drive most current interest; those uses are off-label and the evidence is modest, which we examine honestly elsewhere. Treated as “a previously approved, well-characterized GHRH peptide with a calm legal footing and realistic, modest expectations,” sermorelin is one of the more defensible compounds in the category. Treated as a miracle, it isn’t.